title: Salvage therapy of open, infected surgical wounds: a retrospective review using Techni-Care.
abstract: OBJECTIVE
  To determine outcome of infected surgical wounds treated with 3% para-chloro-meta-xylenol + 3% phospholipid PTC [PCMX-PL] (Techni-Care).
  
  
  METHODS
  Retrospective review of patient records.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  Thirty consecutively treated patients (sixteen male, fourteen female) who had developed open infected wounds (twenty-one abdominal [seventy percent], nine extremity [thirty percent]). Mean patient age was 50.1 years. All wounds were treated with commonly practiced wound care techniques (e.g., debridement, frequent dressing changes using saline or topical antibiotics, and, in most cases, parenteral antibiotics) for an extended period of time prior to intervention (mean = 35 days).
  
  
  METHODS
  PCMX-PL, a topical microbicide, was used as adjunctive therapy. Eight outcome parameters were analyzed: (1) patient morbidity and mortality; (2) wound healing; (3) number of debridements; (4) wound culture results; (5) leukocytosis (peripheral white blood cell count > 10,000 cells/microl); (6) number of febrile days (temperature > 101 degrees F); (7) length of hospital stay; and (8) number of days of intensive care.
  
  
  RESULTS
  No treatment failures or adverse reactions to PCMX-PL were seen. Twenty (sixty-seven percent) wounds were healed or had been successfully closed while ten (thirty-three percent) were granulating well at sixty-day follow-up. The number of debridements, positive wound cultures, white-blood-cells, and febrile days decreased after PCMX-PL treatment began.
  
  
  CONCLUSIONS
  Despite severe underlying diseases, all patients were discharged from the hospital with closed or healing wounds. We recommend treatment with PCMX-PL as an adjunctive therapy for infected wounds particularly when standard care measures have failed.
authors.affiliation: Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.
authors.forename: B C
authors.initials: BC
authors.lastname: Grubbs
authors.forename: C L
authors.initials: CL
authors.lastname: Statz
authors.forename: E M
authors.initials: EM
authors.lastname: Johnson
authors.forename: M E
authors.initials: ME
authors.lastname: Uknis
authors.forename: J T
authors.initials: JT
authors.lastname: Lee
authors.forename: D L
authors.initials: DL
authors.lastname: Dunn
mesh_terms: D000328:Adult; D000368:Aged; D000891:Anti-Infective Agents, Local / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000494:pharmacology / Q000627:therapeutic use*; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D013530:Surgical Wound Infection / Q000188:drug therapy*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*; D014992:Xylenes / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000891:Anti-Infective Agents, Local; D004338:Drug Combinations; D010743:Phospholipids; D014992:Xylenes; C007027:chloroxylenol